Abiopharma

🔍 Kastelein Johannes Jacob Pieter (Executive)

Company: NewAmsterdam Pharma Co N.V. (NAMS)

Report Date: 2025-08-21

Detailed Transactions and Holdings:

• Sold 50,000 shares of Ordinary Shares at $24.29 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 119,302.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 42,342 shares of Ordinary Shares at $25.08 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 76,960.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 7,658 shares of Ordinary Shares at $25.49 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 69,302.00 | transaction_form_type: 4 | Footnotes: F4, F2

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.73 per share to $24.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F2: The ordinary shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.39 per share to $25.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.39 per share to $25.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.